The final frontier of capitalist expansion is no longer the deep sea or outer space; it is the human mind. China’s National Medical Products Administration has approved the world's first commercially available implantable brain-computer interface (BCI). Developed by Borui Kang Medical Technology, the system is designed to restore movement in paralyzed patients by translating neural signals into commands. While framed as a medical miracle, the approval marks a historic step toward the commercial colonization of human neural pathways.

In the West, Nia Therapeutics has received FDA Breakthrough Device Designation for its own AI-guided brain implant aimed at treating memory loss. The convergence of AI and neurotechnology is creating a high-stakes growth market where human performance and cognitive health are being commodified. As the Pentagon partners with OpenAI to explore unrestricted military applications, the line between therapy and enhancement is blurring. The risk of 'bio-surveillance'—where corporate and state actors can monitor or even stimulate neural activity—is no longer a theoretical concern.

We are witnessing the emergence of a 'neural commons' that is being enclosed before it can even be understood. Much like the generic drug revolution shattered the patent monopolies on weight-loss medications in the Global South, the neurotech industry is moving to establish intellectual property over the very electricity of human thought. The approval in Shanghai places China at the forefront of this race, leveraging state resources to bypass traditional clinical timelines. For the worker of the future, the BCI may not be a choice, but a requirement for participation in an economy governed by agentic AI and autonomous systems.